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Abstract. Background: Increased Lp(a) accelerates atherosclerosis using cholesterol 
deposits in tunica. The purpose of the study was to assess the relationship of decreased Lp(a) 
with lipid profile in patients with dyslipidemia given bay leaf extract [syzygium polyanthum 
(Wight) Walp] treatment. Method: Thirty subjects were divided into 2 groups: group I 
received salam leaf extract therapy 2 x 200 mg and group II received salam leaf extract 
therapy 2 x 300 mg per day capsules for 30 days randomly selected and double blind. 
Examination of Lp(a), total cholesterol, LDL-C, HDL-C and TG before and after research. 
The manufacture of bay leaf extract is done by maseration, the extraction process using 
ethanol 70%, then the extract is inserted in the capsule. Result: In groups I and II there were 
significant differences in variable Lp(a) and lipid profiles after treatment except HDL-C. 
There is a significant correlation between Lp(a) and LDL at salam leaf extract therapy doses 
of 2x200 mg per day. Conclusion: Decrease in Lp(a) is significantly correlated with 
decreased LDL-C. Salam leaf extract therapy can predict decreased cardiovascular risk in 
patients with dyslipidemia. 
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Abstrak. Latar belakang: Peningkatan Lp(a) mempercepat aterosklerosis dengan cara 
deposit  kolesterol pada tunika. Tujuan dari penelitian untuk menilai hubungan penurunan 
Lp(a) dengan profil lipid pada pasien dislipidemia yang diberikan pengobatan ekstrak daun 
salam [syzygium polyanthum (Wight) Walp]. Metode: Tiga puluh subjek penelitian dibagi 
atas 2: kelompok I  menerima terapi ekstrak daun salam 2 x 200 mg dan kelompok II 
menerima terapi kapsul ekstrak daun salam 2 x 300 mg perhari selama 30 hari yang dipilih 
secara acak tersamar ganda,. Dilakukan pemeriksaan Lp(a), kolesterol total, kolesterol LDL, 
kolesterol HDL dan TG sebelum dan sesudah penelitian. Pembuatan ekstrak daun salam 
dilakukan dengan cara maserasi, dan proses ekstraksi menggunakan ethanol 70%, 
selanjutnya ekstrak dimasukan dalam kapsul. Hasil:  Pada kelompok I dan II terdapat 
perbedaan yang signifikan variable Lp(a) dan profil lipid sesudah pengobatan  kecuali HDL. 
Terdapat korelasi yang signifikan antara Lp(a) dengan LDL pada dosis  2x200 mg perhari 
kapsul ekstrak daun salam. Kesimpulan: Penurunan Lp(a) berkorelasi signifikan dengan 
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penurunan kolesterol LDL. Pengobatan kapsul ekstrak daun salam dapat memprediksi 
penurunan risiko kardiovaskular pada pasien dyslipidemia.   
Kata Kunci: Lp(a), Profil Lipid, Dyslipidemia., Syzygium Polyanthum (Wight) Walp 
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1 Introduction 
Increased levels of Lp(a) have the potential to increase the risk of cardiovascular disease through 
prothrombotic/ anti-fibrinolitic effects because Lp(a) has a homologous structural with 
plasminogens and plasmin but has no fibrinolytic activity. Increased Lp(a) accelerates 
atherosclerosis by means of cholesterol deposits in tunica.[1] To raise awareness of Lp(a), an 
expert panel from the National Cholesterol Education Program Adult Treatment Panel, the 
European Atherosclerosis Society, and the National Lipid Association  made efforts to advise 
clinicians on screening and modulating increased Lp(a). [3] 
Lp(a) particles consist of apolipoprotein (a), glycoproteins, encoded  by the LPA gene and bound 
to apolipoprotein B of LDL. [2]  CAD risk is associated with Lp(a) molar concentration and apo(a) 
size, and both are independent risk factors for CAD. 
From previous research, it concluded there was no clear evidence that statin treatment can lower 
levels of Lp(a). [5] Administration of bay leaf extract (Syzygium polyanthum) for 30 days at doses 
of 2x200 mg and 2x300 mg can significantly decrease the level of Lp(a) (25.52  +  31.36 vs 22.66  
+  31.12 ng/dL,  p = 0.001 and 27.81  +  33.79 vs 25.65  +  33.23) ng/d,  p = 0.013, respectively). 
[6] 
The purpose of the study was to assess the relationship of decreased Lp(a) with lipid profile in 
patients with dislipidemia given the treatment of bay leaf extract. 
2 Methods 
Dyslipidemia is  determined as an increase  or  decrease in low-density lipoprotein (LDL) 
cholesterol, or  a  decrease in high-density lipoprotein cholesterol (HDL)  as  an important risk  
factor  against coronary heart disease (CHD) and  stroke.[7] The subject research is divided into 
2:  group I received bay leaf extract therapy 2 x 200 mg   and group II received extract therapy 2 
x 300 mg daily for 30 days randomly selected and double blind, monitored eating compliance and 
consumption of bay leaf extract capsules. Examination of  Lp(a), total cholesterol, LDL-C, HDL-
C and TG before and after research. The manufacture of bay leaf extract is done by means of 
maceration, the extraction process using ethanol 70%, then the extract is included in the  capsule. 
[8] Method of measuring Lp(a) using monoclonal anti-apo(a) antibodies and commercial kits 
measure Lp(a) using radial immunodiffusion assay. [9] 
Journal of Endocrinology, Tropical Medicine, and Infectiouse Disease (JETROMI) Vol. 02, No. 4, 2020                        185                                                          
Data were analyzed using the SPSS-21 application. Independent T Test or Man Whitney U 
analytical statistical analysis is used to test the differences in numerical variables between group 
I and group II. The Dependent T or Wilcoxon test to test differences in numerical variables in 
each research group before and after was given a superman correlation treatment and test. 
Differences are considered statistically meaningful when the value of p<0.05. 
3 Results 
In table 1. there is no significant difference except total cholesterol and Lp(a) between groups 1 
and group II. 
Table 1 Basic research data 
Variable Group I (n = 15) 
meanSD 




Gender: W/M             15 / 0               14/ 1  
Age (year) 50.40 + 5.22 50.07 + 4.73 0.818 
WC (cm) 88,33 + 7,18 92,36 + 8,54 0.207 
BMI  (kg/m2) 27.54 + 3.22 27.40 + 0.97 0.836 
FBG (mg/dL) 94,20 + 15,03 91,47 + 85,00 0.604 
TC (mg/dL) 229,13 + 14,99 271,73 + 52,17 0.005* 
LDL-C (mg/dL) 155,00 + 22,55 175,73 + 35,40 0.066 
HDL-C (mg/dL) 51,13 + 7,73 49,33 + 8,53 0.550 
TG (mg/dL) 149,93 + 70,56 202,80 + 114,57 0.139 
Lp(a) (mg/dL) 25,52  + 31,36 27,81  + 33,79 0.013* 
Note: D: day; WC: waist circumference; BMI: body mass index; FBG: fasting blood sugar; TC: total 
cholesterol; LDL-C: low density lipoprotein; HDL-C: high density lipoprotein; TG: triglyceride: Lp(a): 
lipoprotein (a); *p<0.05 
In table 2. There is a significant difference between variable lipid profiles and Lp(a) after 
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Kelompok I (n = 15) 
 Mean + SD 
Kelompok II  (n = 15) 
 Mean + SD 
D0 D30 pa D0 D30 pb 
WC (cm) 91,46+4,43 91,50+4,37 0,056 93,33+1,71 93,36+1,65 0,317 
BMI (kg/m2) 27,54+3.21 27.53+3,19 1,000 27,39+1,71 27,39+0,95 0,635 
FBG (mg/dL) 94,20+15,03 89,05+13,24 0.116* 91,46+18,27 88,06+16,47 0,880 
TC (mg/dL) 229,13 + 14,99 217,53 + 23,10 0,012*  271,73 + 52,17 225,93 + 30,80 0,002* 
LDL-C (mg/dL) 155,00 + 22,55 145,67 + 29,37 0,035* 175,73+ 35,40 145,72+ 33,10 0,001* 
HDL-C (mg/dL)  51,13 + 7,73 50,07 + 7,5 0,318 49,33 + 8,53 47,73 + 5,80 0,344 
TG (mg/dL) 149,93 + 70,56 112,13 + 37,92 0,009* 202,80 + 114,57 138,60 + 49,76 0,016* 
Lp(a) (mg/dL) 25,52+31,36 22,66+31,12 0,001* 27,81+33,79 25,65+33,23 0,013* 
Note: D: day; WC: waist circumference; BMI: body mass index; FBG: fasting blood sugar; TC: total 
cholesterol; LDL-C: low density lipoprotein; HDL-C: high density lipoprotein; TG: triglyceride: Lp(a): 
lipoprotein (a); *p<0.05 
In table 3, there is a significant correlation between Lp(a) and LDL-C with a dose of bay leaf 
extract 400 mg per day (r: 0,561, p: 0.030*). 
Table 3 Correlation between Lp (a) with anthropometric variables and lipid profiles 
Variabel 
Group I Group II 
r p r p 
WC (cm) 0,360 0.188 0,109 0,699 
BMI (mg/dL) 0,025 0,929 -0,209 0,454 
FBG (mg/dL) 0,181 0,465 0,725 0,002 
TC (mg/dL) 0,490 0,64 - 0,182 0,510 
LDL-C (mg/dL) 0,561 0.030* 0.425 0,114 
HDL-C (mg/dL) -0,244 0,381 -0,579 0,019* 
TG (mg/dL) 0,079 0,781 0,221 0,428 
Note: D: day; WC: waist circumference; BMI: body mass index; FBG: fasting blood sugar; TC: total cholesterol; 
LDL-C: low density lipoprotein; HDL-C: high density lipoprotein; TG: triglyceride: Lp(a): lipoprotein (a); 
*p<0.05 
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4 Discussion 
Bay leaves contain tannins, galokatekin, flavonoids, saponins (triterpenoids), and essential oils 
(seskuiterpen). In addition, bay leaves also contain several vitamins, including vitamin A, vitamin 
C, vitamin E, thiamin, riboflavin, niacin, vitamin B6, vitamin B12, and folate. The results of in 
vitro studies show flavonoids work as inhibition of the enzyme HMG-CoA reductase so that 
cholesterol synthesis decreases. Saponins can form complex bonds that are insoluble with 
cholesterol derived from food, bind to bile acids forming micelles and increase cholesterol 
binding by fiber so that cholesterol cannot be absorbed by the gut. Tannin inhibits the absorption 
of fat in the intestine by reacting with mucosal proteins and intestinal epithelial cells .[10]  
The results of the study in mice model dyslipidemia showed that infusion of  bay leaves with 
concentrations of 5%, 10%, 20% for 2 weeks significantly lowered TC (p< 0.05), and  its potency 
was equivalent to simvastatin. [11] Some studies in  families  with  CVD, there is a positive 
correlation between Lp(a) and LDL-C, TC, and Apolipoprotein B, this suggests  there  is a link 
between Lp(a) levels and lipid profiles.  Serum Lp(a) does  not correlate with ESR (r:0.27, 
p:0.028),  MHAQ (r=0.11, p:0.37). [12] In addition to Lp(a) correlated with LDL-C is also 
negatively correlated with TG levels in diabetic patients. Therefore, these results suggest that the 
treatment of diabetic dyslipidemia can indirectly affect the concentration of Lp(a). [13] 
In this study, treatment of bay leaf extract of 2x200 mg per day: decrease in Lp(a) was 
significantly correlated with LDL-C (r: 0.643; p: 0.010), while treatment of bay leaf extract was 
2x300 mg per day, decreased Lp(a) significantly negatively correlated with HDL-C (r: -0.573; p: 
0.026). 
5 Conclusion 
Decreased Lp(a ) is significantly correlated with a decrease  in LDL-C with treatment of bay leaf 
extract. Treatment of bay leaf extract can predict decreased cardiovascular risk in patients with 
dyslipidemia. 
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